Cargando…
A versatile toolkit for overcoming AAV immunity
Recombinant adeno-associated virus (AAV) is a promising delivery vehicle for in vivo gene therapy and has been widely used in >200 clinical trials globally. There are already several approved gene therapy products, e.g., Luxturna and Zolgensma, highlighting the remarkable potential of AAV deliver...
Autores principales: | Li, Xuefeng, Wei, Xiaoli, Lin, Jinduan, Ou, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479010/ https://www.ncbi.nlm.nih.gov/pubmed/36119036 http://dx.doi.org/10.3389/fimmu.2022.991832 |
Ejemplares similares
-
T Cell-Mediated Immune Responses to AAV and AAV Vectors
por: Ertl, Hildegund C. J.
Publicado: (2021) -
Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients
por: Gross, David-Alexandre, et al.
Publicado: (2022) -
Humoral Immune Response to AAV
por: Calcedo, Roberto, et al.
Publicado: (2013) -
Editorial: Immunogenicity and toxicity of AAV gene therapy
por: Bradbury, Allison, et al.
Publicado: (2023) -
Nanobody Technology: A Versatile Toolkit for Microscopic Imaging, Protein–Protein Interaction Analysis, and Protein Function Exploration
por: Beghein, Els, et al.
Publicado: (2017)